Lupin’s Australian subsidiary Generic Health has acquired the global rights for the Goanna brand and the complete range of premium therapeutic oils, rubs and ointments marketed under the brand.
Goanna brand has been trusted by generations of Australians to provide effective relief of muscular aches and pains and other conditions such as arthritis.
Lupin, through its subsidiary Generic Health is excited to add this heritage brand to the existing portfolio of quality prescription and over the counter products and looks forward to continuing the brand’s rich tradition of excellence.
The company intends to add a number of exciting brand extensions to the range that will further reinforce the position of this tried and tested range of products in the Australian market. The brand is being sold by about 83% pharmacies in Australia, which would also go a long way in increasing the company’s reach in the market.
Lupin’s net profit for the fourth quarter surged 64.38% at Rs 243.75 crore as compared to Rs 148.28 crore for the corresponding quarter previous year. Its total income has increased 30.81% at Rs 1223.33 crore for the quarter under review from Rs 935.18 crore in the corresponding previous quarter.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |